Nicotine metabolite ratio (3-Hydroxycotinine/Cotinine) in plasma and urine by different analytical methods and laboratories: Implications for clinical implementation

Cancer Epidemiology Biomarkers and Prevention

Volumn 24, Issue 8, 2015, Pages 1239-1246

  Tanner, Julie Anne ^a,b   Novalen, Maria ^a,b   Jatlow, Peter ^c   Huestis, Marilyn A ^d   Murphy, Sharon E ^e   Kaprio, Jaakko ^f,g   Kankaanpää, Aino ^g   Galanti, Laurence ^h   Stefan, Cristiana ^a   George, Tony P ^a,b   Benowitz, Neal L ⁱ   Lerman, Caryn ^j   Tyndale, Rachel F ^a,b  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

^f UNIVERSITY OF HELSINKI   (Finland)

^g NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^h UNIVERSITY HOSPITAL OF MONT GODINNE   (Belgium)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j UNIVERSITY OF PENNSYLVANIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXYCOTININE; COTININE; NICOTINE; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; HYDROXYCOTININE;

ARTICLE; BLAND ALTMAN ANALYSIS; BLOOD SAMPLING; CLINICAL LABORATORY; CORRELATION COEFFICIENT; ELECTROSPRAY; EXTRACTION; GAS CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY WITH ULTRAVIOLET RADIATION; HUMAN; KIDNEY CONCENTRATING CAPACITY; LIQUID CHROMATOGRAPHY; LIQUID CHROMATOGRAPHY TANDEM MASS SPECTROMETRY; MEASUREMENT; PRIORITY JOURNAL; SMOKING; STATISTICAL PARAMETERS; TANDEM MASS SPECTROMETRY; ULTRAVIOLET RADIATION; URINALYSIS; ANALOGS AND DERIVATIVES; BLOOD; METABOLISM; URINE;

BIOMARKERS; COTININE; HUMANS; NICOTINE;

EID: 84930643731     PISSN: 10559965     EISSN: 15387755     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-14-1381     Document Type: Article

References (23)

1. Nakajima M, Yamamoto T, Nunoya K, Yokoi T, Nagashima K, Inoue K, et al. Characterization of CYP2A6 involved in 3'-hydroxylation of cotinine in human liver microsomes. J Pharmacol Exp Ther 1996;277:1010-5.
2. Messina ES, Tyndale RF, Sellers EM. A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. J Pharmacol Exp Ther 1997;282: 1608-14.
3. Mwenifumbo JC, Tyndale RF. Genetic variability in CYP2A6 and the pharmacokinetics of nicotine. Pharmacogenomics 2007;8:1385-402.
4. Malaiyandi V, Goodz SD, Sellers EM, Tyndale RF. CYP2A6 genotype, phenotype, and the use of nicotine metabolites as biomarkers during ad libitum smoking. Cancer Epidemiol Biomarkers Prev 2006;15:1812-9.
5. Hukkanen J, Jacob P III, Benowitz NL.Metabolism and disposition kinetics of nicotine. Pharmacol Rev 2005;57:79-115.
6. Dempsey D, Tutka P, Jacob P III, Allen F, Schoedel K, Tyndale RF, et al. Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity. Clin Pharmacol Ther 2004;76:64-72.
7. Lerman C, Tyndale R, Patterson F, Wileyto EP, Shields PG, Pinto A, et al. Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation. Clin Pharmacol Ther 2006;79:600-8.
8. Patterson F, Schnoll RA, Wileyto EP, Pinto A, Epstein LH, Shields PG, et al. Toward personalized therapy for smoking cessation: a randomized placebo-controlled trial of bupropion. Clin Pharmacol Ther 2008;84:320-5.
9. Schnoll RA, Patterson F, Wileyto EP, Tyndale RF, Benowitz N, Lerman C. Nicotine metabolic rate predicts successful smoking cessation with transdermal nicotine: a validation study. Pharmacol Biochem Behav 2009;92: 6-11.
10. Lerman CSR, Hawk LW, Cinciripini P, George TP, Wileyto EP, Swan GE, et al. A randomized placebo-controlled trial to test a genetically-informed biomarker for personalizing treatment for tobacco dependence. Lancet Respir Med 2015;3:131-8
11. Falcone M, Jepson C, Benowitz N, Bergen AW, Pinto A, Wileyto EP, et al. Association of the nicotine metabolite ratio and CHRNA5/CHRNA3 polymorphisms with smoking rate among treatment-seeking smokers. Nicotine Tob Res 2011;13:498-503.
12. Zhu AZ, Binnington MJ, Renner CC, Lanier AP, Hatsukami DK, Stepanov I, et al. Alaska Native smokers and smokeless tobacco users with slower CYP2A6 activity have lower tobacco consumption, lower tobacco-specific nitrosamine exposure and lower tobacco-specific nitrosamine bioactivation. Carcinogenesis 2013;34:93-101.
13. Lea RA, Dickson S, Benowitz NL. Within-subject variation of the salivary 3HC/COT ratio in regular daily smokers: prospects for estimating CYP2A6 enzyme activity in large-scale surveys of nicotine metabolic rate. J Anal Toxicol 2006;30:386-9.
14. Mooney ME, Li ZZ,Murphy SE, Pentel PR, Le C, Hatsukami DK. Stability of the nicotine metabolite ratio in ad libitum and reducing smokers. Cancer Epidemiol Biomarkers Prev 2008;17:1396-400.
15. St Helen G, Jacob P III, Benowitz NL. Stability of the nicotine metabolite ratio in smokers of progressively reduced nicotine content cigarettes. Nicotine Tob Res 2013;15:1939-42.
16. St Helen G, Novalen M, Heitjan DF, Dempsey D, Jacob P III, Aziziyeh A, et al. Reproducibility of the nicotine metabolite ratio in cigarette smokers. Cancer Epidemiol Biomarkers Prev 2012;21:1105-14.
17. Chenoweth MJ, Novalen M, Hawk LW Jr, Schnoll RA, George TP, Cinciripini PM, et al. Known and Novel Sources of Variability in the Nicotine Metabolite Ratio in a Large Sample of Treatment-Seeking Smokers. Cancer Epidemiol Biomarkers Prev 2014;23:1773-82.
18. Schnoll RA, George TP, Hawk L, Cinciripini P, Wileyto P, Tyndale RF. The relationship between the nicotine metabolite ratio and three self-report measures of nicotine dependence across sex and race. Psychopharmacology 2014;231:2515-23.
19. Levi M, Dempsey DA, Benowitz NL, Sheiner LB. Prediction methods for nicotine clearance using cotinine and 3-hydroxy-cotinine spot saliva samples II.Model application. J Pharmacokinet Pharmacodyn 2007;34:23-34.
20. Fu I, Woolf EJ, Matuszewski BK. Effect of the sample matrix on the determination of indinavir in human urine byHPLCwith turbo ion spray tandem mass spectrometric detection. J Pharm Biomed Anal 1998;18:347-57.
21. Binnington MJ, Zhu AZ, Renner CC, Lanier AP, Hatsukami DK, Benowitz NL, et al. CYP2A6 and CYP2B6 genetic variation and its association with nicotine metabolism in South Western Alaska Native people. Pharmacogenetics Genomics 2012;22:429-40.
22. Curvall M, Elwin CE, Kazemi-Vala E, Warholm C, Enzell CR. The pharmacokinetics of cotinine in plasma and saliva from non-smoking healthy volunteers. Eur J Clin Pharmacol 1990;38:281-7.
23. Jarvis MJ, Russell MA, Benowitz NL, Feyerabend C. Elimination of cotinine from body fluids: implications for noninvasive measurement of tobacco smoke exposure. Am J Public Health 1988;78:696-8.